Bojungikki-Tang Improves Response to PD-L1 Immunotherapy by Regulating the Tumor Microenvironment in MC38 Tumor-Bearing MiceJaemoo Chun, Mi-Kyung Jeong, Sang‐Min Park et al.|Frontiers in Pharmacology|2022Cited by 21
Safety and Efficacy of Bojungikki-Tang in Advanced NSCLC Patients Receiving Treatment with Immune Checkpoint Inhibitors: Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot TrialMi Mi Ko, Mi-Kyung Jeong, Chang‐Min Choi et al.|International Journal of Environmental Research and Public Health|2023Cited by 7
Efficacy and Safety of Herbal Medicine Bojungikki-Tang in Combination with Pembrolizumab versus Pembrolizumab Monotherapy for Stage IV Non-Small Cell Lung Cancer: Study Protocol for a Randomized, Open-Label, Double-Arm, Multicenter TrialEunbyul Cho, Mi-Kyung Jeong, Seung Hun Jang et al.|Integrative Cancer Therapies|2025Cited by 6
Bojungikki-Tang Enhances the Effect of PD-1 Blockade in a Syngeneic Murine Model of Lung CarcinomaJaemoo Chun, Mi-Kyung Jeong, Han Na Kang et al.|Processes|2022Cited by 6
Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse modelSung‐yoon Yang, Mi-Kyung Jeong, Jin-Mu Yi et al.|Frontiers in Pharmacology|2023Cited by 6